Advertisement
DMAC vs IRD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Buy and IRD is a Hold.
DMAC in upward trend: 10-day moving average crossed above 50-day moving average on September 22, 2026
The 10-day moving average for DMAC crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on DMAC as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for DMAC just turned positive on October 22, 2026. Looking at past instances where DMAC's MACD turned positive, the stock continued to rise in 44 of 51 cases over the following month. The odds of a continued upward trend are 86%.
DMAC moved above its 50-day moving average on September 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for DMAC moved above the 200-day moving average on October 13, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +10.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 216 of 256 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 120 of 157 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for DMAC moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.139) is normal, around the industry mean (2.973). P/E Ratio (-11.986) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IRD in downward trend: 10-day moving average moved below 50-day moving average on October 14, 2026
The 10-day moving average for IRD crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRD as a result. In 91 of 109 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for IRD turned negative on September 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
IRD moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IRD's RSI Indicator exited the oversold zone, 26 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRD advanced for three days, in 214 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-24.473) is normal, around the industry mean (2.973). P/E Ratio (-2.961) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMAC | IRD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 55 Fair valued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 40 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 37 | 42 | |
P/E GROWTH RATING 1..100 | 68 | 71 | |
SEASONALITY SCORE 1..100 | 50 | 32 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRD's Valuation (7) in the null industry is somewhat better than the same rating for DMAC (55) in the Biotechnology industry. This means that IRD’s stock grew somewhat faster than DMAC’s over the last 12 months.
DMAC's Profit vs Risk Rating (40) in the Biotechnology industry is somewhat better than the same rating for IRD (100) in the null industry. This means that DMAC’s stock grew somewhat faster than IRD’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as IRD (100) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
DMAC's Price Growth Rating (37) in the Biotechnology industry is in the same range as IRD (42) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
DMAC's P/E Growth Rating (68) in the Biotechnology industry is in the same range as IRD (71) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
| DMAC | IRD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 89% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 82% |
| Advances ODDS (%) | 2 days ago 84% | 2 days ago 83% |
| Declines ODDS (%) | 9 days ago 81% | 4 days ago 82% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 76% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMAC’s FA Score shows that 0 FA rating(s) are green while IRD’s FA Score has 1 green FA rating(s).
- DMAC’s FA Score: 0 green, 5 red.
- IRD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMAC’s TA Score shows that 8 TA indicator(s) are bullish while IRD’s TA Score has 4 bullish TA indicator(s).
- DMAC’s TA Score: 8 bullish, 3 bearish.
- IRD’s TA Score: 4 bullish, 6 bearish.
Price Growth
DMAC (@Biotechnology) experienced а +7.34% price change this week, while IRD (@Biotechnology) price change was +0.37% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
DMAC is expected to report earnings on Nov 11, 2026.
IRD is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IRD and
Correlation & Price change
A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
|---|---|---|---|---|
| IRD | 100% | -7.17% | ||
| ARRY - IRD | 35% Loosely correlated | -3.23% | ||
| PRME - IRD | 34% Loosely correlated | -2.10% | ||
| CABA - IRD | 31% Poorly correlated | -1.30% | ||
| DMAC - IRD | 31% Poorly correlated | -0.69% | ||
| NGNE - IRD | 31% Poorly correlated | -6.90% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MUB | 103.24 | 0.79 | +0.77% |
| iShares National Muni Bond ETF (MUB) | |||
| MTGP | 42.74 | 0.32 | +0.76% |
| WisdomTree Mortgage Plus Bond Fund (MTGP) | |||
| CHY | 11.62 | N/A | N/A |
| Calamos Convertible and High Income Fund | |||
| PSF | 18.01 | -0.02 | -0.11% |
| COHEN & STEERS SELECT PREFERRED AND Income FUND | |||
| XTJL | 42.55 | -0.23 | -0.53% |
| Innovator U.S. Equity Accelerated Plus ETF - July (XTJL) | |||